Study Investigating the Safety, Tolerability, and PK, PD, of CB-0406
NCT04467684
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
90
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy Volunteers
Interventions
DRUG:
CB-0406 100 mg
DRUG:
CB-0406 200 mg
DRUG:
CB-0406 400 mg
DRUG:
CB-0406 800 mg
DRUG:
CB-0406 1,000 mg
DRUG:
Matched placebo
Sponsor
Gilead Sciences